Gyre Therapeutics (GYRE) Return on Capital Employed (2011 - 2026)

Gyre Therapeutics (GYRE) has 16 years of Return on Capital Employed data on file, last reported at 5.96% in Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 5.96%, down 1550.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 5.96% (down 1550.0% YoY), and the FY2025 annual result was 2.38%, down 1355.0% from the prior year.
• Return on Capital Employed slipped to 5.96% in Q1 2026 per GYRE's latest filing, from 2.1% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 68.07% in Q1 2023 and troughed at 230.48% in Q1 2022.
• A 5-year average of 32.94% and a median of 2.1% in 2025 frame the typical range for Return on Capital Employed.
• On a YoY basis, Return on Capital Employed climbed as much as 29855 bps in 2023 and fell as far as 17577 bps in 2023.
• A 5-year view of Return on Capital Employed shows it stood at 20.16% in 2022, then plunged by 872 bps to 155.61% in 2023, then soared by 110 bps to 15.28% in 2024, then slumped by 86 bps to 2.1% in 2025, then sank by 384 bps to 5.96% in 2026.
• Business Quant data shows GYRE's Return on Capital Employed at 5.96% in Q1 2026, 2.1% in Q4 2025, and 8.59% in Q3 2025.